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Abstract
Introduction: The taxanes paclitaxel and docetaxel are widely used in the treatment of breast, ovarian, and other
cancers. Although their cytotoxicity has been attributed to cell-cycle arrest through stabilization of microtubules,
the mechanisms by which tumor cells die remains unclear. Paclitaxel has been shown to induce soluble tumor
necrosis factor alpha (sTNF-a) production in macrophages, but the involvement of TNF production in taxane
cytotoxicity or resistance in tumor cells has not been established. Our study aimed to correlate alterations in the
TNF pathway with taxane cytotoxicity and the acquisition of taxane resistance.
Methods: MCF-7 cells or isogenic drug-resistant variants (developed by selection for surviving cells in increasing
concentrations of paclitaxel or docetaxel) were assessed for sTNF-a production in the absence or presence of
taxanes by enzyme-linked immunosorbent assay (ELISA) and for sensitivity to docetaxel or sTNF-a by using a
clonogenic assay (in the absence or presence of TNFR1 or TNFR2 neutralizing antibodies). Nuclear factor (NF)-B
activity was also measured with ELISA, whereas gene-expression changes associated with docetaxel resistance in
MCF-7 and A2780 cells were determined with microarray analysis and quantitative reverse transcription polymerase
chain reaction (RTqPCR).
Results: MCF-7 and A2780 cells increased production of sTNF-a in the presence of taxanes, whereas docetaxel-
resistant variants of MCF-7 produced high levels of sTNF-a, although only within a particular drug-concentration
threshold (between 3 and 45 nM). Increased production of sTNF-a was NF-B dependent and correlated with
decreased sensitivity to sTNF-a, decreased levels of TNFR1, and increased survival through TNFR2 and NF-B
activation. The NF-B inhibitor SN-50 reestablished sensitivity to docetaxel in docetaxel-resistant MCF-7 cells. Gene-
expression analysis of wild-type and docetaxel-resistant MCF-7, MDA-MB-231, and A2780 cells identified changes in
the expression of TNF-a-related genes consistent with reduced TNF-induced cytotoxicity and activation of NF-B
survival pathways.
Conclusions: We report for the first time that taxanes can promote dose-dependent sTNF-a production in tumor
cells at clinically relevant concentrations, which can contribute to their cytotoxicity. Defects in the TNF cytotoxicity
pathway or activation of TNF-dependent NF-B survival genes may, in contrast, contribute to taxane resistance in
tumor cells. These findings may be of strong clinical significance.
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Introduction
Taxanes are a family of chemotherapy drugs used to
treat various human cancer types [1-6]. The most com-
mon family members include paclitaxel and docetaxel,
which block microtubule depolymerization, inducing
cell-cycle arrest at mitosis and multinucleation of tumor
cells [7,8]. Taxanes also reduce tumor angiogenesis and
cell migration, while stimulating the immune system
against neoplasms [9-11].
Another mechanism for taxane cytotoxicity may
involve tumor-necrosis factor (TNF)-a production,
because paclitaxel has been shown to augment TNF-a
levels in murine macrophages [12]. TNF-a is a mem-
brane-integrated cytokine (mTNF-a) generally produced
in activated macrophages and monocytes [13], which
can be released from cells in a soluble form (sTNF-a)
by the action of the metalloproteinase ADAM-17 [14].
The release of sTNF-a from cells can then induce cell
death or a cell-survival response, depending on the
receptor to which it binds: TNFR1 or TNFR2, respec-
tively (reviewed in [15]. Although mTNF-a binds with
equal affinity to both receptors, sTNF-a preferentially
binds to TNFR1, which has a death-effector domain that
induces caspase-8 cleavage and apoptosis [16,17]. Unlike
TNFR1, TNFR2 does not contain a death domain. Lim-
ited reports suggest that TNFR2 activation promotes
cell death, although the mechanism for this is poorly
understood and may require the presence of TNFR1
[18,19]. Nevertheless, TNFR2 has been shown to induce
NF-B activity and cell survival [20].
Many mechanisms associated with resistance to tax-
anes have been identified in vitro, such as overexpres-
sion of the drug-efflux pump Abcb1, b-tubulin gene
mutations, or overexpression of b-tubulin (type III);
however, their clinical relevance remains unclear [21,22].
Multiple mechanisms of taxane resistance likely occur
simultaneously in cells [23]. To restore tumor sensitivity
to taxanes appreciably in cancer patients, all clinically
relevant mechanisms of docetaxel resistance must be
identified.
To better understand the various pathways associated
with taxane resistance, our laboratory selected MCF-7
breast tumor cells for survival in increasing concentra-
tions (doses) of paclitaxel (MCF-7TAX-1 cells) [24] or
docetaxel (MCF-7TXT cells) [23]. Increased Abcb1
expression and decreased taxane uptake occurred on
acquisition of taxane resistance in these cells, but a pan-
ABC transporter inhibitor that restored taxane uptake
had no or only a partial effect on drug sensitivity in
these cells [23]. Therefore, additional mechanisms must
contribute to taxane resistance, and these cell lines may
serve as an attractive tool for assessing the possible role
of TNF-a and other pathways in taxane cytotoxicity or
resistance.
This study reveals for the first time that docetaxel
concentrations of 3 nM or greater induce tumor necro-
sis factor (TNF) expression in MCF-7 cells, and that
acquisition of docetaxel resistance can be temporally
correlated with elevations in cellular TNF-a levels resis-
tance to TNF-a cytotoxicity, degradation of TNFR1, and
promotion of TNFR2-induced survival pathways through
the activation of NF-B. In further support of the role
of TNF in taxane cytotoxicity and resistance, we also
report that both paclitaxel and docetaxel can induce
TNF-a expression in A2780 ovarian carcinoma cells. In
addition, we report the consistent alteration in networks
of TNF-related genes on acquisition of docetaxel resis-
tance in breast and ovarian tumor cells.
Materials and methods
Cell culture and maintenance
MCF-7 cells from the American Tissue Culture Collection
(catalog number HTB-22) were cultured or selected for
survival in increasing doses of docetaxel or paclitaxel, as
previously described [23,24]. The initial concentrations of
docetaxel and paclitaxel used to begin selection (dose 1)
were 0.51 and 0.56 nM, respectively. Cells selected to doc-
etaxel concentrations of 1.11 nM (dose 8, MCF-7TXT8),
3.33 nM (dose 9, MCF-7TXT9), 5.00 nM (dose 10, MCF-
7TXT10), 15 nM (dose 11, MCF-7TXT11), and 45 nM (dose
12, MCF-7TXT12) were used in this study. Numbers in sub-
scripts of cell-line names refer to the maximal docetaxel
dose level to which the cells were exposed. The paclitaxel-
resistant cell line used in this study was selected in an
identical manner to a final concentration of 6.64 nM pacli-
taxel (MCF-7TAX-1 cells; hyphenated number indicates the
first cell-line selection, not drug dose). MCF-7 cells were
also “selected” in the absence of taxanes to passage num-
bers similar to those of drug-selected cells to control for
genotypic or phenotypic changes associated with long-
term culture ("co-cultured control” MCF-7CC cells).
A2780 ovarian carcinoma cells from the European Collec-
tion of Cell Cultures were also selected for resistance to
docetaxel in an identical manner (A2780DXL cells), includ-
ing the creation of “co-cultured control” A2780CC cells
(Armstrong et al., unpublished data).
Measurement of sTNF-a and sTNFR1 in cell-culture media
Concentrated proteins from the medium of 2 million
MCF-7CC, MCF-7TXT, or A2780 cells (grown in culture
in the absence or presence of various concentrations of
paclitaxel or docetaxel) were assessed for levels of
sTNF-a or sTNFR1 by using ELISA kits from R&D Sys-
tems, following the manufacturer’s instructions.
Clonogenic assays
Cellular sensitivity to TNF-a or docetaxel was assessed
by using a clonogenic assay, as described previously
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[24]. Docetaxel resistance factors for the cell lines were
determined by dividing the median inhibitory concentra-
tion (IC50) for docetaxel in the taxane-resistant cell lines
by the IC50 for MCF-7CC cells. In some experiments,
cells were exposed to 1 μg/ml cycloheximide, TNFR1 or
TNFR2 neutralizing antibodies from R&D Systems (both
at 5 μg/ml), or a peptide from Calbiochem Laboratories
(La Jolla, CA), which potently blocks NF-B function by
inhibiting translocation of the NF-B complex into the
nucleus [25] (SN-50, 7 μg/ml). A control peptide at the
same concentration (SN-50 M) was used in the latter
experiments to assess the specificity of NF-B inhibition.
Immunoblotting analysis
MCF-7CC, MCF-7TXT, and MCF-7TAX-1 cells were incu-
bated in the absence or presence of 20 ng/ml TNF-a for
24 hours. Cells were extracted in RIPA buffer, and 100
μg of extract proteins assessed for the expression of spe-
cific proteins by using standard immunoblotting proce-
dures, as previously described [24]. Antibodies used in
these experiments included TNFR1-, TNFR2-, and IB-
specific antibodies from Cell Signaling Technology
(Danvers, MA) and a mouse-derived GAPDH antibody
from Santa Cruz Laboratories. Densitometric quantita-
tion of bands generated by the IB antibody was per-
formed by using AlphaEaseFC software (Alpha
Innotech, San Leandro, CA). Band intensity was normal-
ized relative to GAPDH band intensity.
Quantification of TNFR1 and TNF-a transcript levels by
RTqPCR
The levels of TNFR1 and TNF-a transcripts in MCF-7CC
and MCF-7TXT10 cells were assessed as described
previously [26] by using the following primers: TNFR1:
forward, 5’-ACTGCCTCAGCTGCTCCAAAT-3’; reverse,
5’-CCGGTCCACTGTGCAAGAA-3’, TNF-a: forward, 5’-
TCTTCTCGAACCCCGAGTGA-3’, reverse, 5’-GGAGC
TGCCCCT-CAGCTT-3’; and S28: forward, 5’-TCCATC
ATCCGCAATGTAAAAG-3’, reverse, 5’-GCTTCTGCGT
CTGACTCCAAA-3’.
Measurement of NF-B activity
MCF-7CC and MCF-7TXT cells were cultured in the pre-
sence or absence of 50 nM docetaxel for 24 hours. The
activity of the NF-B p65 and p50 subunits in 10 μg of
nuclear extracts was assessed as outlined in the TransAM
NF-B Family ELISA kit (Active Motif, Carlsbad, CA).
Readings at 450 nm were normalized to the sum of all read-
ings on the plate to compare across triplicate experiments.
Identification of changes in gene expression associated
with the acquisition of docetaxel resistance
Agilent 4 × 44 k human genome oligonucleotide arrays
were used to profile differences in gene expression
between MCF-7TXT and MCF-7cc cells at selection dose
10 and between docetaxel-resistant and wild-type A2780
ovarian carcinoma cells (A2780DXL and A2780 cells,
respectively) at the maximally tolerated dose by using
MIAME standards [27]. RNA was isolated from each
cell line by using RNeasy Mini kits (Qiagen, Mississauga,
ON), and 500 ng of each RNA preparation was labeled
and amplified by using Agilent Quick Amp labeling kits.
The labeling and array hybridization procedures were
performed as per the manufacturer’s protocol for a two-
color microarray experiment.
Identification of differences in gene expression associated
with docetaxel resistance
The hybridized microarrays were scanned by using Agi-
lent scanners and feature extraction software (version
10_7_3_1), and differentially expressed genes associated
with the acquisition of docetaxel resistance were identi-
fied by using Partek Genomic Suite (Partek, Inc., St.
Louis, MO). The background-corrected intensity values
were used for analysis. A three-way ANOVA was per-
formed to identify significant changes in gene expression
by using the Method of Moments [28]. Genes with
greater than twofold differences in gene expression were
selected with a false discovery rate of either 0.05 or 0.01
[29]. The data from these array experiments were
deposited in the National Centre for Biotechnology
Information Gene Expression Omnibus database (acces-
sion number GSE26129) [30].
Network-based analysis of gene expression
To determine whether the previously described changes
in gene expression associated with acquisition of doce-
taxel resistance in breast or ovarian tumor cells may
reflect changes in the function of specific biochemical
pathways in these cells, the genes identified as being
associated with docetaxel resistance were subjected to
functional-interaction (FI) network analysis [31]. In
brief, the FI network covers ~50% of the human pro-
teome representing more than 200,000 functional inter-
actions. Pairwise shortest paths among genes of interest
in the FI network were calculated and hierarchically
clustered (based on the average-linkage method). Clus-
ters were then selected containing more than 90% of
altered genes. To calculate a P value for the average
shortest path, we performed a 1,000-fold permutation
test by randomly selecting the same number of genes
from the biggest connected network component. A
minimum spanning tree algorithm was used to find lin-
kers that connected all genes of interest in one subnet-
work [32]. We used the Markov Cluster Algorithm
(MCL) [33] with inflation of 1.6 for network clustering.
Only the biggest clusters with numbers of proteins not
less than 2% of the total network were taken into
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account. All network diagrams were drawn by using
Cytoscape [34]. The functional enrichment analysis for
pathways was based on a binominal test. A false discov-
ery rate was calculated based on 1,000 permutations on
all genes in the FI network. This network-based analysis
was also applied to another dataset that documents dif-
ferences in gene expression between docetaxel-resistant
and parental MDA-MB-231 breast cancer cell lines
(Gene Expression Omnibus (GEO) accession number
GSE28784).
Confirmation of microarray-based changes in gene
expression by reverse transcription quantitative
polymerase chain reaction
A number of the TNF-a-related genes in these networks
were further assessed for expression in wild-type and
docetaxel-resistant MCF-7 and A2780 cells with reverse
transcription quantitative polymerase chain reaction
(RTqPCR) by using the primers depicted in Table 1 and
the method described earlier.
Results
Docetaxel increases sTNF-a production in MCF-7CC and
A2780 cells
MCF-7CC and A2780CC cells secreted low levels of sTNF-
a (1.69 × 10-18 ± 0.40 × 10-18 g/cell and 3.02 × 10-18 ±
0.28 × 10-18 g/cell, respectively). These levels were not
significantly changed when cells were treated with 0.1 to
1 nM docetaxel. In contrast, media extracted from MCF-
7CC cells treated with ≥ 3 nM docetaxel produced signifi-
cantly elevated levels of sTNF-a (Figure 1a). A2780 cells
produced even greater amounts of TNF-a in response to
docetaxel (Figure 1a). Interestingly, the taxane paclitaxel
(at concentrations ≥ 15 nM) induced even higher levels
of sTNF-a production than docetaxel in A2780 cells (Fig-
ure 1b). Given the stronger induction of TNF-a by doce-
taxel in A2780 cells, we then assessed whether upstream
mechanisms responsible for TNF-a induction in A2780
cells were similar to those of macrophages. Comparable
to the induction of TNF-a expression by lipopolysacchar-
ides in macrophages [35], we observed that TNF-a
induction by docetaxel in A2780 cells was dependent on
NF-B, because an inhibitor of this transcription factor
(SN-50) significantly reduced the induction of TNF-a by
docetaxel (Figure 1c). The basal amount of sTNF-a pro-
duction and the magnitude of docetaxel-induced sTNF-a
production varied between experiments (compare Figures
1a and 1c for 45 nM docetaxel). Nevertheless, the sTNF-
a levels were consistently and substantially higher in cells
treated with taxanes. The extent of TNF-a induction by
the taxanes appeared to decrease at higher docetaxel con-
centrations, possibly because of other deleterious effects
of these agents on cells at the higher doses.
Selection of MCF-7 cells in increasing concentrations of
docetaxel results in acquisition of progressive docetaxel
resistance above a threshold dose
Increasing exposure of MCF-7 cells to docetaxel up to a
con{centration of 1.1 nM (dose 8, MCF-7TXT8 cells) did
not affect docetaxel sensitivity (Figure 2). However, selec-
tion to 3.33 nM docetaxel (dose 9, MCF-7TXT9 cells)
resulted in an 11.4-fold resistance to docetaxel. Above this
threshold, resistance factors increased to 16.6, 32.8, and
184 for cells selected to final docetaxel concentrations of 5
nM (dose 10, MCF-7TXT10 cells), 15 nM (dose 11, MCF-
7TXT11 cells), and 45 nM (dose 12, MCF-7TXT12 cells),
respectively. Interestingly, MCF-7TXT cells exhibited an
even greater cross-resistance to paclitaxel, with resistance
factors of 148 and 251 at selection doses 11 and 12,
respectively [23]. The resistance factor for MCF-7 cells
selected for resistance to paclitaxel at the maximally toler-
ated dose (MCF-7TAX-1 cells) was 42. These cells also
exhibited strong cross-resistance to docetaxel (46-fold)
[24]. In contrast, ovarian A2780 cells could be selected for
resistance to considerably higher concentrations of doce-
taxel. A2780DXL cells at their maximally tolerated dose
Table 1 Primers selected for confirmation of changes in the expression of tumor necrosis factor-a-related genes by
reverse transcription quantitative polymerase chain reaction
Gene Forward primer Reverse primer
S28 5’TCC ATC ATC CGC AAT GTA AAG-3’ 5’-GCT TCT CGC TCT GAC TCC AAA-3’
TNFAIP3 5’-GAC CAT GGC ACA ACT CAT CTC A-3’ 5’-GTT AGC TTC ATC CAA CTT TGC GGC ATT G-3’
TNFSF10 5’-CGT GTA CTT TAC CAA CGA GCT GA-3’ 5’-ACG GAG TTG CCA CTT GAC TTG-3’
TNFSF13 5’-ACT CTC AGT TGC CCT CTG GTT G-3’ 5’-GGA ACT CTG CTC CGG GAG ACT C-3’
TNFSF14 5’-TTT GCT CCA CAG TTG GCC TAA TC-3’ 5’-CAA TGA CTG TGG CCT CAC CTT C-3’
TLR1 5’-GGT ACC AGG CCC TCT TCC TCG TTA G-3’ 5’-TAG GAA CGT GGA TGA GAC CG TTT TT-3’
TLR6 5’-GCA AAA ACC CTT CAC CTT GTT TTT C-3’ 5’-CCA AGT CGT TTC TAT GTG GTT GAG G-3’
BIRC3 5’-TGT TGG GAA TCT GGA GAT GA-3’ 5’-CGG ATG AAC TCC TGT CCT TT-3’
TNFR1 5’-ACT GCC TCA GCT GCT CCA AAT-3’ 5’-CCG GTC CAC TGT GCA AGA A-3’
TNFa 5’-TCT TCT CGA ACC CCG AGT GA-3’ 5’-GGA GCT GCC CCT CAG CTT-3’
Reaction conditions were as described in Materials and methods, and expression was assessed relative to that of S28, the internal reference gene.
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(405 nM) exhibited ~4,000-fold resistance to docetaxel
(Armstrong et al., unpublished data).
Effects of docetaxel on sTNFa in MCF-7CC and MCF-7TXT
cell lines
MCF-7CC and MCF-7TXT8 cells secreted low amounts of
TNF-a (11.5 × 10-18 ± 0.4 × 10-18 g/cell and 5.5 × 10-18
± 1.4 × 10-18 g/cell, respectively). When these cell lines
were exposed to 50 nM docetaxel, no significant differ-
ence in sTNF-a secretion was observed (Figure 3a). In
contrast, untreated MCF-7TXT9 and MCF-7TXT10 cells
secreted 31.8-fold and 18.2-fold higher levels of sTNF-a
than did MCF-7CC cells (P < 0.0001), and addition of 50
nM docetaxel increased sTNF-a production a further
1.62-fold and 1.27-fold, respectively (P < 0.01). sTNF-a
levels returned to basal levels in MCF-7TXT11 and MCF-
7TXT12 cells, even after treatment with 50 nM docetaxel.
No differences in sTNF-a levels were observed between
MCF-7CC and MCF-7TAX-1 cells, in the presence or
absence of docetaxel (data not shown). TNF-a transcript
levels in MCF-7TXT10 cells (relative to S28 expression)
were 198.5 ± 30.5 higher than the levels of this tran-
script in MCF-7CC cells (Figure 3b), suggesting that ele-
vated secretion of sTNF-a is likely due to dramatically
increased expression of TNF-a transcripts and protein.
MCF-7TXT and MCF-7TAX-1 cells are resistant to TNF-a-
induced cytotoxicity
TNF-a (10 ng/ml) reduced colony formation in a clono-
genic assay by 79.8% ± 6.0% and 66.6% ± 1.7% for
Figure 1 Docetaxel or paclitaxel-induced production of soluble tumor-necrosis factor alpha (sTNF-a) in MCF-7CC and A2780 cells. (a)
The mean concentration of sTNF-a (± standard error) (n = 4) found in the medium of MCF-7CC (black) or A2780 (white) cells cultured for 48
hours with varying amounts of docetaxel. (b) The mean concentration of sTNF-a (± standard error) (n = 4) found in the medium of A2780 cells
cultured for 48 hours with varying amounts of paclitaxel. (c) The effect of docetaxel (45 nM) and/or the nuclear factor (NF)-B inhibitor SN-50 (7
μg/ml) on sTNF-a production in A2780 cells. The significance of differences in sTNF-a levels was assessed by using a Student t test; P values of
< 0.01 and < 0.001 are represented by ** and *** symbols, respectively.
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MCF-7CC and MCF-7TXT8 cells, respectively (P <
0.0001) (Figure 4a). In contrast, MCF-7TXT9, MCF-
7TXT10, MCF-7TXT11, and MCF-7TAX-1 cells all had simi-
lar levels of colony formation in the absence or presence
of 10 ng/ml TNF-a, indicating substantial TNF-a resis-
tance. TNF actually increased colony formation in
MCF-7TXT12 cells, possibly because of a high level of
activation of growth and survival pathways in these cells
at the highest selection dose, some of which are TNF-a
dependent (see Discussion). The cell lines were also cul-
tured in the presence of varying concentrations of TNF-
a. Colony formation was very strongly reduced in MCF-
7CC cells in the presence of 50 or 100 ng/ml TNF-a (P
< 0.0001) (Figure 4b). Reductions in colony formation
were much smaller for MCF-7TXT10 cells treated with
50 ng/ml or 100 ng/ml TNF-a, again indicating resis-
tance to TNF-a cytotoxicity in docetaxel-resistant cells.
MCF-7TAX-1 cells treated with 10 ng/ml TNF-a formed
similar numbers of colonies as did untreated cells, sug-
gesting that these cells were also resistant to TNF-a.
However, TNF-a concentrations of 50 or 100 ng/ml
induced strong reductions in colony formation relative
to MCF-7TXT10 cells, suggesting greater resistance to
TNF-a in the former cell line than in the latter.
Figure 2 Acquisition of resistance to docetaxel or paclitaxel in MCF-7 cells. Sensitivity of MCF-7CC cells (broken lines) and taxane-selected
MCF-7 cells (solid lines) was measured after selection for survival to dose levels 8 (MCF-7TXT8), 9 (MCF-7TXT9), 10 (MCF-7TXT10), 11 (MCF-7TXT11), or
12 (MCF-7TXT12), or at the maximally tolerated dose of paclitaxel (MCF-7TAX-1 cells). Mean survival fractions (± standard error) are plotted, and the
significance of differences in docetaxel sensitivity between the taxane-selected and control cell lines was assessed by using a Student t test (n =
5); P values of < 0.05, < 0.01, and < 0.001 are represented by the *, **, and *** symbols, respectively.
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TNFR1 protein levels (but not transcript levels) are
reduced on acquisition of docetaxel resistance in MCF-7
cells
Unlike TNFR2, the levels of TNFR1 protein (as mea-
sured in immunoblotting experiments) decreased on
acquisition of docetaxel resistance at dose 9 (MCF-
7TXT9 cells) and remained low in MCF-7TXT10 and
MCF-7TXT12 cells (Figure 5a). Interestingly, RTqPCR
analysis revealed no significant differences in TNFR1
transcript expression between these cell lines (Figure
5b). Similar soluble TNFR1 (sTNFR1) levels were
observed in MCF-7CC and MCF-7TXT8 cells (Figure 5c),
although levels decreased in MCF-7TXT9 and MCF-
7TXT10 cells (P < 0.001). sTNFR1 levels then returned to
those of MCF-7TXT8 cells as docetaxel-selective pressure
was increased.
Induction of docetaxel resistance in MCF-7 cells through
application of a TNFR1 neutralizing antibody
Significant differences in colony formation were
observed between TNFR1 neutralizing antibody-treated
MCF-7CC cells and untreated cells when incubated with
1.23 nM (P < 0.0001), 0.41 nM (P = 0.0002), 0.14 nM (P
= 0.0006), and 0.046 nM (P < 0.0001) docetaxel (Figure
5d). Nonlinear regression curve-fitting programs
revealed that MCF-7CC cells incubated with the TNFR1
Figure 3 Levels of soluble tumor-necrosis factor alpha (sTNF-a) in the medium of MCF-7CC and MCF-7TXT cells on exposure to
docetaxel. The ability of MCF-7 cells to produce sTNF-a was measured by using an enzyme-linked immunosorbent assay (ELISA) after selection
for survival to docetaxel dose levels 8 (MCF-7TXT8), 9 (MCF-7TXT9), 10 (MCF-7TXT10), 11 (MCF-7TXT11), or 12 (MCF-7TXT12), or to the maximally
tolerated dose of paclitaxel (MCF-7TAX-1 cells). After selection, the cells at the various selection doses were assessed for their production of sTNF-
a in the absence (white bars) or presence (black bars) of 50 nM docetaxel (a). The results presented are the mean levels (± standard error) for
five independent experiments, and the significance of differences in sTNF-a levels between MCF-7CC and MCF-7TXT cells was assessed by using a
Student t test; P values of < 0.01 and < 0.001 are represented by the ** and *** symbols, respectively. (b) Expression of TNF-a and S28
transcripts measured with RTqPCR by using cDNA preparations from MCF-7CC and MCF-7TXT cells (dose level 10).
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neutralizing antibody were about 2.25-fold more resis-
tant to docetaxel than were untreated cells, consistent
with a role for the TNF-a pathway in docetaxel
cytotoxicity.
Activation of NF-B on acquisition of docetaxel resistance
Unlike MCF-7TAX-1 cells, MCF-7TXT10 cells had 35%
lower IB levels than did MCF-7CC cells (P = 0.03) (Fig-
ure 6a). Measurement of NF-B binding in nuclear
extracts from MCF-7 and MCF-7TXT8 cells revealed low
binding of NF-B p65 and p50 subunits to the NF-B
transcription factor binding site (Figures 6b and 6c). In
contrast, nuclear extracts from MCF-7TXT9 and MCF-
7TXT10 cells exhibited more than threefold higher levels
of subunit binding to the NF-B sequence compared
with equivalent extracts from MCF-7CC cells (P < 0.05).
This binding was reduced as cells were exposed to
higher docetaxel selection doses. Interestingly, 50 nM
docetaxel induced even higher levels of p65 and p50
subunit binding in MCF-7CC and MCF-7TXT cells,
except when docetaxel selection doses were more than
15 nM (doses 11 and 12).
Promotion of TNF-a cytotoxicity in MCF-7TXT10 cells by
cycloheximide or a TNFR2 neutralizing antibody
As previously observed, exposure of MCF-7CC cells to
10 ng/ml TNF-a strongly decreased colony formation in
a clonogenic assay, whereas MCF-7TXT10 cells exhibited
significant resistance to TNF-a (Figure 7a). The addition
of the protein-synthesis inhibitor cycloheximide, 5 μg/
ml, restored the ability of TNF-a to be cytotoxic to
MCF-7TXT10 cells, while having only a small additional
effect on TNF-a cytotoxicity in MCF-7CC cells. These
observations suggested that a protein, possibly NF-B, is
critical for maintaining resistance to TNF-a.
To test this hypothesis, and because NF-B is acti-
vated on TNF-a binding to TNFR2, resulting in
enhanced expression of survival genes [20], we theorized
that docetaxel cytotoxicity might be increased in MCF-
7TXT10 cells on addition of a TNFR2-neutralizing anti-
body or an inhibitor of NF-B function. Supporting this
conjecture, we observed a greater reduction in colony
formation for TNFR2-neutralizing antibody-treated cells
than untreated cells when treated with 41.2 nM (P =
0.0007), 13.7 nM (P = 0.005), 4.5 nM (P = 0.006), or 1.7
nM (P = 0.01) docetaxel (Figure 7b). Nonlinear regres-
sion curve-fitting for three independent experiments
revealed that the TNFR2 neutralizing antibody rendered
MCF-7TXT10 cells 2.13-fold more sensitive to docetaxel
than were untreated cells. Moreover, as shown in Figure
7c the peptide SN-50, which contains the nuclear locali-
zation signal of NF-B and thus blocks the transcription
factor translocation to the nucleus [25], increased
docetaxel cytotoxicity to an even greater degree in
MCF-7TXT10 cells (7.1-fold). In contrast, a control pep-
tide (SN-50 M), in which critical basic amino acids
within the nuclear localization signal are replaced with
uncharged amino acids, had no effect on docetaxel sen-
sitivity (Figure 7c).
Network-based analysis of genes associated with the
acquisition of docetaxel resistance
Assessment of microarray data by using an FI network
approach (see Materials and methods) revealed 2,235
Figure 4 Sensitivity of MCF-7CC, MCF-7TXT, and MCF-7TAX-1 cells to tumor-necrosis factor (TNF)-a in clonogenic assays. The effect of
docetaxel selection dose on colony formation in MCF-7CC and MCF-7TXT cells in the absence or presence of 10 ng/ml TNF (a). Colony formation
in MCF-7, MCF-7TXT10, and MCF-7TAX-1 cells in the presence of 0 ng/ml, 10 ng/ml, 50 ng/ml, or 100 ng/ml TNF-a (b). The mean numbers of
colonies (± standard error) are depicted, and the significance of differences in TNF-a sensitivity between MCF-7CC and MCF-7TXT cells at the
various selection doses was assessed by using a Student t test; P values of < 0.05, < 0.01, and < 0.001 are represented by the *, **, and ***
symbols, respectively.
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genes that were differently expressed between parental
and docetaxel-resistant MCF-7 breast cancer cell lines
(fold-change > 2.0 and FDR ≤ 0.05). Of these, 834
(37.3%) were in the FI network, and hierarchic cluster-
ing reduced this to a set of 753 of the most intercon-
nected candidates. This gene set was then used for
further analyses. The average shortest-distance calcula-
tion showed that genes in this set were linked together
much more tightly than would be expected by chance
alone (P < 0.001), indicating that these differentially
expressed genes occupy a small corner of the large FI
network space. A subnetwork was built from these 753
genes by adding the minimum number of linker genes
required to form fully connected networks involving
these genes. The resulting networks consisted of 938
genes, 185 of which were linkers. A Markov clustering
algorithm was then used to identify clusters of proteins
(coded by the genes) that are highly interconnected with
each other and less connected to the outside world.
This algorithm identified 14 clusters consisting of more
than 20 genes, including a cluster of 22 TNF-associated
genes and eight linkers (Figure 8a).
We used an identical approach to identify clusters of
differentially expressed genes between wild-type and
docetaxel-resistant A2780 ovarian carcinoma cells. Of
955 genes that were differentially expressed between the
two cell lines, a network of 11 TNF-related genes and
three linkers was identified (Figure 8b). When the same
approach was used to identify networks of genes differ-
entially expressed between docetaxel-sensitive and
Figure 5 Tumor-necrosis factor receptor (TNFR)1 and TNFR2 levels in MCF-7CC and MCF-7TXT cell lines. (a) Protein levels of TNFR1, TNFR2,
and GAPDH in MCF-7CC, MCF-7TXT8, MCF-7TXT9, MCF-7TXT10, and MCF-7TXT12 cells. (b) TNFR1 and S28 transcript levels in MCF-7CC and MCF-7TXT10
cells determined with reverse transcription quantitative PCR (RTqPCR). (c) The mean concentration (± standard error; n = 4) of secreted TNFR1
protein was examined in the cell lines by using an ELISA. (d) The ability of MCF-7CC cells to form colonies in a clonogenic assay at various
concentrations of docetaxel in the absence (broken line) or presence (solid line) of 5 μg/ml of a TNFR1 neutralizing antibody (R&D Systems).
Error bars represent standard error of the mean. Significance of differences was assessed by using a Student t test; P values of < 0.05, < 0.01, and
< 0.001 are represented by *, **, and *** symbols, respectively.
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docetaxel-resistant MDA-MB-231 cells (data obtained
from GEO, accession number GSE28784), a cluster of
22 TNF-related genes and three linkers was identified
(see Figure 8c).
Confirmation of changes in the expression of TNF-a-
dependent genes by RTqPCR
The expression of a selected number of genes within the
previously identified TNF-a signaling networks was
quantitatively assessed with RTqPCR. As shown in Fig-
ure 9, a generally strong concordance was noted
between changes in gene expression identified by micro-
array analysis and those determined by RTqPCR (12 of
14 gene-expression changes assessed). Six TNF-a-
dependent genes were confirmed to have altered expres-
sion on selection of MCF-7 cells for resistance to
docetaxel, including TNFSF13, TNFSF10, TLR6,
TNFAIP3, TNFSF14, and BIRC3 (the latter two genes
being upregulated 30-fold and 21-fold, respectively).
Three of these genes were also upregulated in A2780DXL
cells (BIRC3, TLR6, and TNFSF10, which increased
expression almost 300-fold).
Discussion
Although taxanes are known to inhibit cell division by pre-
venting microtubule depolymerization and inducing multi-
nucleation [8,36], it is unclear whether these are their sole
mechanisms of tumor cell growth arrest/death in vitro and
in vivo. Paclitaxel has been shown to increase sTNF-a
release from murine macrophages [12,37], although the
levels used in those studies would be unachievable in
patients, and docetaxel had no effect on TNF-a expression
Figure 6 Nuclear factor (NF)-B activity in MCF-7CC, MCF-7TXT, and MCF-7TAX-1 cells. (a) Levels of I-B and a reference protein
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in MCF-7CC, MCF-7TXT8, MCF-7TXT10, and MCF-7TAX-1 cells in the absence or presence of 10
ng/ml Tumor-necrosis factor (TNF)-a. Protein levels were assessed in immunoblotting experiments with quantification of band intensities by
using densitometry. The effect of selection for survival in increasing doses of docetaxel on the activity of the NF-B p65 (b) and p50 (c) subunits
in the absence or presence of docetaxel also was examined by using an ELISA. Mean (± standard error) values are plotted, and the significance
of differences between MCF-7CC and taxane-resistant cells or differences between treated and untreated cells was assessed by using a Student t
test; P values of < 0.05, < 0.01, and < 0.001 are represented by *, **, and *** symbols, respectively.
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in the same study. In our study, we showed for the first
time that docetaxel (at concentrations between 3 and 45
nM) can stimulate TNF-a production and sTNF-a release
from both breast and ovarian tumor cells. Such concentra-
tions are clearly in the range of plasma levels of docetaxel
in breast cancer patients after docetaxel infusion (10 to 75
nM) [38] and are likely sufficiently high to induce TNF
expression in even poorly vascularized tumors. This newly
identified TNF-dependent mechanism of docetaxel action
may also account for its reported immunomodulatory
activity [11,39]. In addition, we show in this article that
paclitaxel treatment (at 5 and 15 nM concentrations) can
dramatically increase sTNF-a release from ovarian tumor
cells.
Our study also illustrates that the acquisition of doce-
taxel resistance in breast tumor cells temporally corre-
lates with increased production and release of sTNF-a
from cells, despite the ability of sTNF-a to be cytotoxic
to cells [40]. However, the onset of docetaxel resistance
in MCF-7 cells (at docetaxel selection doses ≥ 3.33 nM)
also correlated with strongly reduced levels of TNFR1,
which would block the ability of TNF-a to induce cell
death. Although the mechanism responsible for TNFR1
reduction remains undefined, neither changes in TNFR1
transcript levels nor increased levels of sTNFR1 in the
media were found, suggesting that the receptor was not
shed from cells by the ADAM-17 protease [14]. In fact,
MCF-7TXT9 and MCF-7TXT10 cells exhibited decreased
levels of sTNFR1 in the medium in which it was grown.
It is possible that increased levels of sTNFa produced
by these cells bound to sTNFR1 in the medium, pre-
venting its detection by the TNFR1 antibody. Taken
together, our findings suggest that downregulation of
TNFR1 occurs posttranscriptionally, because of either
reduced translation of the TNFR1 transcript or
increased TNFR1 proteolysis.
A recent study [41] found that TNF-a or paclitaxel
induced NF-B activity in C2C12 myotubes. However,
Figure 7 Effect of various agents on colony formation in MCF-7CC or MCF-7TXT10 cells. MCF-7CC or MCF-7TXT10 cells were assessed for their
ability to form colonies after exposure to 10 ng/ml tumor-necrosis factor (TNF)-a, 10 μg/ml cycloheximide, or a combination of both agents for
24 hours (a). The ability of MCF-7TXT10 cells to form colonies in increasing concentrations of docetaxel in the absence (broken line) or presence
(solid line) of a TNFR2 neutralizing antibody (5 μg/ml) was also examined (b). The effects of an NF-B inhibitor SN-50 (7 μg/ml; broken gray line)
or a control peptide SN-50 M (7 μg/ml; broken black line) on the colony-forming behavior of MCF-7TXT10 cells also were examined (c). Mean
survival fractions (± standard error) are plotted. Significance of differences was assessed by using a Student t test; P values of < 0.05, < 0.01, and
< 0.001 are represented by *, **, and *** symbols, respectively.
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paclitaxel did not induce increased TNF-a production,
and inhibition of TNFR1 blocked TNF-a-induced NF-
B activation but did not abolish paclitaxel-induced NF-
B activity [41]. It is important to note that, in these
studies, TNF-a levels were assessed only 4 hours after
treatment with paclitaxel (10 nM to 10 μM).
Whereas docetaxel selection doses between 3 and 5
nM resulted in highly elevated sTNF-a production,
higher selection doses (≥ 15 nM) did not. This was
despite the ability of the drug to induce TNF-a produc-
tion in wild-type cells over a large concentration range
(Figure 1). This may be explained by the increased
expression of the Abcb1 drug transporter and reduced
docetaxel uptake that we observed in MCF-7TXT11 and
MCF-7TXT12 cells. Expression was maximal at the high-
est selection doses (≥ 15 nM) [42]. We propose that
docetaxel accumulates at sufficient concentrations to
induce production of sTNF-a in MCF-7TXT9 and MCF-
7TXT10 cells. However, at or above 15 nM docetaxel,
MCF-7TXT cells exhibit reduced drug uptake, such that
docetaxel accumulation is insufficient to stimulate TNF-
a production.
The mechanism for resistance to taxanes and TNF-a
in MCF-7TAX-1 cells appears to differ from that of
Figure 8 Networks of tumor-necrosis factor (TNF)-a-related genes that exhibited alterations in gene expression on selection for
resistance to docetaxel in MCF-7 breast carcinoma (a), A2780 ovarian carcinoma (b), or MDA-MB-231 breast carcinoma (c) cells. Gene
expressions in the wild-type and docetaxel-resistant cell lines were compared with microarray analysis, after which differentially expressed genes
were grouped into functional interaction networks, as described in Materials and methods. Genes upregulated in docetaxel-resistant cells are
depicted by using red circles, whereas genes downregulated in docetaxel-resistant cells are depicted by using blue circles. Linker genes are
depicted in green diamonds. Direct activating or inhibitory interactions are indicated with the symbols ® and ┤, respectively. Indirect
interactions involving additional proteins are depicted with dashed lines.
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Figure 9 Use of reverse transcription quantitative PCR (RTqPCR) to assess differences in the expression of Tumor-necrosis factor (TNF-
a)-related genes between MCF-7CC and MCF-7TXT cells (a) and between A2780 and A2780DXL cells (b). For genes in which qPCR
confirmed the changes in gene expression identified by cDNA microarray analysis, representative amplification plots are shown. S28 was used as
the reference gene.
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MCF-7TXT cells. TNFR1 levels were equivalent in MCF-
7TAX-1 and MCF-7CC cells (data not shown), and IB
levels were also unchanged during selection for pacli-
taxel resistance (Figure 6). Because only cells exposed to
the maximally tolerated dose of paclitaxel were retained
during selection of MCF-7TAX-1 cells, it is likely that
cells selected at lower doses could have exhibited ele-
vated production of TNF-a and TNF-a-mediated NF-
B activation. However, survival by circumventing the
TNF-a ability to stimulate TNFR1-induced cytotoxicity
must lie downstream of the receptor. MCF-7TAX-1 cells
are also high expressors of Abcb1 [24]. Interestingly,
another paclitaxel-resistant MCF-7 cell line (MCF-7TAX-
2 cells) [23] retained sensitivity to TNF-a (data not
shown), suggesting that defects in the TNF-a pathway
are not critical for taxane resistance in vitro. Neverthe-
less, considering that three of the four taxane-resistant
cell lines exhibited alterations in TNF-a signaling and
that docetaxel has been shown to increase sTNF-a
levels in both breast and ovarian tumor cells, it appears
that we have identified a common but unknown
mechanism of taxane cytotoxicity and resistance that
warrants further study for its potential clinical relevance.
To provide further support for a general involvement
of the TNF-a pathway in docetaxel cytotoxicity and in
the induction of docetaxel resistance, we also showed in
this study that selection of breast and ovarian tumor
cells for resistance to docetaxel results in changes in the
expression of networks of genes related to TNF-a sig-
naling (Figure 8 and Table 2). Quite strikingly, the vast
majority of the upregulated genes depicted in Table 2
code for proteins that are TNF-ligand family members,
TNF-receptor family members, TNF receptor-associated
proteins, TNF-dependent activators of NF-B, or pro-
teins that help promote degradation of the inhibitor of
NF-B (IB). Other upregulated genes are TNF-depen-
dent inhibitors of apoptosis. Downregulated genes code
for proteins that inhibit the activation of NF-kB or pro-
mote apoptosis. The net effect of the changes in gene
expression would thus be to promote the ability of TNF
to augment NF-B-dependent cell survival, while block-
ing its ability to induce tumor cell death via activation
of TNFR1.
The findings of our study may have significant clinical
relevance. A presentation at the 26th annual meeting of
the European Association of Urology in 2011 [43]
revealed that serum levels of proinflammatory cytokines,
including TNF-a, increased 2 days after administration
of docetaxel to patients with castration-resistant prostate
cancer. Interestingly, these changes in cytokine expres-
sion correlated with the induction of apoptosis and with
clinical response. In addition, a study presented recently
at the American Association for Cancer Research, 101st
Annual Meeting [44], revealed that, in patients with
serous epithelial ovarian carcinoma, pretreatment tumor
expression of various genes within the TNF-a and NF-
B signaling networks could be used to distinguish
between responders and nonresponders to paclitaxel/
carboplatin chemotherapy. It also was shown in a small
study involving patients with locally advanced breast
cancer that tumor levels of nuclear (activated) NF-B
could be used to distinguish between responders and
nonresponders to neoadjuvant anthracycline- and/or
taxane-based chemotherapy regimens [45]. These and
other studies strongly support the likely clinical signifi-
cance of the findings. For example, because TNF-a has
been shown to reduce tumor vascularization in mice
through its effects on TNFR1-expressing endothelial
cells [46], the reported ability of docetaxel to affect
tumor angiogenesis [10] may be through an ability of
the drug to promote sTNFa-mediated decreases in
tumor vascularization. Moreover, one of the well-estab-
lished dose-limiting toxicities associated with docetaxel
chemotherapy in breast cancer patients is fatigue [47],
and high TNF levels have been shown to correlate with
fatigue onset in cancer patients [48]. Given our findings
of docetaxel-induced TNF-a production, perhaps these
two phenomena are linked.
Finally, a previous clinical study used a TNF-decoy
receptor (entanercept) to permit patients to tolerate
higher doses of docetaxel without significant toxicity
[49]; however, given our findings, it is not surprising
that these blockers would create a greater tolerance to
docetaxel, unfortunately at the likely expense of lesser
anti-tumor efficacy. Our findings further question the
utility of administering docetaxel to cancer patients on
TNF-a blockers for treatment of co-morbid inflamma-
tory diseases.
Conclusions
Our study provides evidence for the first time that tax-
anes can induce sTNF-a expression in two tumor cell
lines of different tissue origin. Although this would pro-
mote the cytotoxicity of docetaxel, continued exposure
to the drug appears to result in a downregulation of
TNF-a-mediated cytotoxicity, while promoting TNF-a-
dependent activation of NF-kB-dependent cell-survival
pathways and the inhibition of apoptosis. In addition,
although drug-resistance studies often involve selection
of cells to maximally tolerated drug doses [50,51], our
study illustrates the critical role that the drug-selection
dose may play on the mechanisms by which tumor cells
acquire chemotherapy resistance. At lower doses of tax-
anes (3 to 5 nM), TNF-a-mediated activation of NF-B-
dependent cell-survival pathways appears to be an
important mechanism of taxane resistance, whereas at
selection doses ≥ 15 nM docetaxel, the drug induces
overexpression of Abcb1, resulting in reduced
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Table 2 Tumor-necrosis factor a (TNFa)- and nuclear factor (NF)-B-related genes associated with the acquisition of
docetaxel resistance in MCF-7 breast tumor cells, MDA-MB-231 breast tumor cells, and A2780 ovarian carcinoma cells
Gene Direction and magnitude of
change in expressiona
Role of gene product Refs.
Changes in the expression of TNFa- or NF-B-related genes in MCF-7TXT10 cells relative to MCF-7CC10 cells
TNF Increased 12.6, 1.43 Binds to TNFR1 to promote cell death and to TNFR2 to stimulate expression of NF-B-
dependent survival genes
[54,55]
TNFSF10 Increased 6.88 TNF-like ligand that binds to DcR2 to activate NF-B-dependent survival genes; also
called TRAIL
[56]
TNFRSF19 Increased 16.5, 1.64 Member of the TNF-receptor family that binds to lymphotoxin alpha, activates NF-B-
mediated transcription
[57]
TNFRSF14 Increased, 4.24 TNF-receptor family member, interacts with members of the TNFR-associated factor
(TRAF) family and activates NF-B and AP-1
[58]
TNFSF13 Increased, 3.07 Binds to TNFRSF13B to promote NF-B activation; also called APRIL [59]
BIRC3 Increased, 52.2 Member of a family of proteins that inhibits apoptosis by binding to TNFR-associated
factors TRAF1 and TRAF2
[60]
TLR2 Increased, 5.19 Stimulates NF-B activation [61]
TRIM38 Increased, 4.22, 7.28 Removes Lys63-linked ubiquitin chains from TRAF2 and TRAF6, negatively regulating NF-
B activity
[62]
TNFRSF6B Decreased, -2.02 Member of the TNF-receptor superfamily, which, on binding of TNF, inhibits cell
proliferation and induces apoptosis
[63]
TRAF3IP2 Decreased, -2.14 Associates with and activates I-B kinase, leading to the liberation of NF-B from its
complex with I-B
[64]
Changes in the expression of TNFa- or NF-B-related genes in A2780DXL cells relative to A2780 cells (MTD)
TNFSF13 Increased, 2.10 Binds to TNFRSF13B to promote NF-B activation; also called APRIL [59]
TNFRSF11B Increased, 2.01 Decoy receptor for the TNF-related apoptosis-inducing ligand TRAIL; confers resistance
to TNF- and TRAIL-induced apoptosis
[65]
CARD14 Increased, 2.19, 1.31 Associates with guanylate kinase members that interact with BCL10 and activate NF-B [66]
IRAK4 Increased, 3.70, 3.86 Required for the optimal transduction of IL-1-induced signals, including the activation of
IRAK-1, NF-B, and JNK
[67]
TLR1 Increased, 2.79 Acts via MYD88 and TRAF6 to stimulate NF-B activation, cytokine secretion, and the
inflammatory response
[68]
TLR6 Increased, 2.26, 1.57 Also acts via MYD88 and TRAF6 to stimulate NF-B activation, cytokine secretion, and
the inflammatory response
[68]
BIRC3 Increased, 8.83 Member of a family of proteins that inhibits apoptosis by binding to TNFR-associated
factors TRAF1 and TRAF2
[60]
RFFL Increased, 2.15, 2.13 Endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-B
activation
[69]
TRAF3IP2 Increased, 2.16 Associates with and activates I-B kinase, leading to the liberation of NF-B from its
complex with I-B
[64]
SMPD3 Decreased, -1.59, -2.03 Translocates to the plasma membrane in response to TNF-a in a time- and dose-
dependent manner
[70]
SOX9 Decreased, -30.8 Protein whose expression and activity is negatively regulated by TNF-dependent NF-B
activation
[71]
Changes in the expression of TNFa- or NF-B-related genes in docetaxel-resistant MB-231 cells relative to A2780 cells
CAST Increased, 2.44 Inhibits degradation of NF-B to prolong NF-B activation [72]
BCL10 Increased, 3.48 Potent activator of NF-B activity [73]
RPS6KA3 Increased, 5.95 Phosphorylates I-B and activates NF-B in response to TNF [74]
MAP2K5 Increased, 3.54 A survival protein highly expressed in MCF-7 breast tumor cells resistant to etoposide
and TNF-a
[75]
MKNK2 Increased, 1.76 Promotes TNF-a biosynthesis at the posttranscriptional levels [76]
[75]
TNFRSF10B Decreased, -1.67 Also known as TRAIL receptor 2; stimulates apoptosis via FADD [77]
FADD Decreased, -2.00 A component of the caspase 8-activating complex induced by TNF-a binding to TNFR1 [78]
CRADD Decreased, -2.43 An adaptor protein that promotes TNFa-induced apoptosis through interaction with the
TNFR1-interacting protein RIP
[79]
TRAF1 Decreased, -2.39 Negatively regulates the ability of TNFR2 to promote cell proliferation and NF-B
activation in T cells
[80]
MKNK1 Decreased, -2.00 Promotes TNF-a-mediated mRNA degradation [81]
Full-genome oligo-based microarray experiments were performed comparing differences in gene expression between wild-type and docetaxel-resistant MCF-7
cell lines. Differentially expressed genes were then classified into various functional interaction networks, as described in Materials and methods. Information on
the identities and roles of genes associated with TNF-a signaling are presented in tabular form, with particular emphasis on the products of genes that are
known to play a role in the induction of NF-B-dependent survival genes or in the inhibition of apoptosis. aNumbers represent the fold increase (positive
numbers) or decrease (negative numbers) in expression of the gene as revealed by one or more oligo probes on the Agilent 44K human microarrays.
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accumulation of docetaxel into cells and a consequent
reduction in docetaxel-stimulated TNF-a production.
Since the concentration of docetaxel within patient
tumors is typically lower than that present in the vascu-
lature, perhaps the pathways associated with resistance
to lower concentrations of docetaxel are of greater clini-
cal relevance. This may explain why Abcb1 inhibitors
have had little ability to reverse resistance to taxanes in
cancer patients [52,53]. In addition, given that some
cancer patients with inflammatory diseases may be tak-
ing TNF blockers, this newly identified role for TNF in
docetaxel cytotoxicity may be of particular importance,
suggesting that these blockers may compromise the effi-
cacy of docetaxel chemotherapy.
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